Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements (TBZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00642057
Expanded Access Status : Available
First Posted : March 24, 2008
Last Update Posted : February 9, 2021
Sponsor:
Information provided by (Responsible Party):
Joseph Jankovic, Baylor College of Medicine

Brief Summary:
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Condition or disease Intervention/treatment
Hyperkinetic Movement Disorders Drug: tetrabenazine

Detailed Description:
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Layout table for study information
Study Type : Expanded Access
Official Title: Compassionate Use of Tetrabenazine in the Treatment of Hyperkinesias

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: tetrabenazine
    25 mg titrated to optimal dose per patient

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
  • Willing to sign informed consent.
  • Willing to comply with procedures required as part of this study.

Exclusion Criteria:

  • Those subjects unwilling to comply with study requirements.
  • Subjects unable to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00642057


Contacts
Layout table for location contacts
Contact: Rory D Mahabir, MBA 713-798-5989 rory.mahabir@bcm.edu

Sponsors and Collaborators
Joseph Jankovic
Additional Information:
Layout table for additonal information
Responsible Party: Joseph Jankovic, Professor, Neurology-PDCMDC, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00642057    
Other Study ID Numbers: H-721
First Posted: March 24, 2008    Key Record Dates
Last Update Posted: February 9, 2021
Last Verified: February 2021
Keywords provided by Joseph Jankovic, Baylor College of Medicine:
chorea
dyskinesia
hyperkinetic
Additional relevant MeSH terms:
Layout table for MeSH terms
Movement Disorders
Hyperkinesis
Central Nervous System Diseases
Nervous System Diseases
Dyskinesias
Neurologic Manifestations
Tetrabenazine
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs